The Excretion of Dexamphetamine and Its Derivatives
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Dextroamphetamine PI 202006
HIGHLIGHTS OF PRESCRIBING INFORMATION • Glaucoma (4) 5.4 Long-Term Suppression of Growth Cardiovascular • Agitated states (4) Monitor growth in children during treatment with stimulants. Patients who are not growing or gaining weight as expected may need to have their treatment interrupted. Palpitations. There have been isolated reports of cardiomyopathy associated with chronic amphetamine use. These highlights do not include all the information needed to use DEXTROAMPHETAMINE saccharate, AMPHET- • History of drug abuse (4) Careful follow-up of weight and height in children ages 7 to 10 years who were randomized to either methylphenidate or non-medication treatment groups over Central Nervous System AMINE aspartate monohydrate, DEXTROAMPHETAMINE sulfate, AMPHETAMINE sulfate extended-release capsules • During or within 14 days following the administration of monoamine oxidase inhibitors (MAOI) (4, 7.1) 14 months, as well as in naturalistic subgroups of newly methylphenidate-treated and non-medication treated children over 36 months (to the ages of 10 to 13 years), Psychotic episodes at recommended doses, overstimulation, restlessness, irritability, euphoria, dyskinesia, dysphoria, depression, tremor, tics, aggression, anger, safely and effectively. See full prescribing information for DEXTROAMPHETAMINE saccharate, AMPHETAMINE aspar- suggests that consistently medicated children (i.e., treatment for 7 days per week throughout the year) have a temporary slowing in growth rate (on average, a total of logorrhea, dermatillomania, paresthesia (including formication), and bruxism. tate monohydrate, DEXTROAMPHETAMINE sulfate, AMPHETAMINE sulfate extended-release capsules. ----------------------------------------------------------- WARNINGS AND PRECAUTIONS ----------------------------------------------------------- about 2 cm less growth in height and 2.7 kg less growth in weight over 3 years), without evidence of growth rebound during this period of development. -
Preparation of Amphetamines From
Europäisches Patentamt *EP001442006B1* (19) European Patent Office Office européen des brevets (11) EP 1 442 006 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.7: C07C 209/00 of the grant of the patent: 24.08.2005 Bulletin 2005/34 (86) International application number: PCT/US2002/034400 (21) Application number: 02802245.7 (87) International publication number: (22) Date of filing: 28.10.2002 WO 2003/037843 (08.05.2003 Gazette 2003/19) (54) PREPARATION OF AMPHETAMINES FROM PHENYLPROPANOLAMINES VERFAHREN ZUR HERSTELLUNG VON AMPHETAMINEN AUS PHENYLPROPANOLAMINEN PREPARATION D’AMPHETAMINES A PARTIR DE PHENYLPROPANOLAMINES (84) Designated Contracting States: • REINER LUCKENBACH: "Beilstein Handbuch AT BE BG CH CY CZ DE DK EE ES FI FR GB GR der Organischen Chemie, vol. XII, 4th Ed., 4th IE IT LI LU MC NL PT SE SK TR Suppl., p. 2586 to 2591" 1984 , SPRINGER VERLAG , BERLIN . HEIDELBERG . NEW YORK (30) Priority: 29.10.2001 US 20488 TOKYO XP002235852 page 2586 -page 2591 • HANS-G. BOIT: "Beilsteins Handbuch der (43) Date of publication of application: Organischen Chemie, vol. XII, 4th Ed., Third 04.08.2004 Bulletin 2004/32 Suppl. page 2664 to page 2669" 1973 , SPRINGER VERLAG , BERLIN . HEIDELBERG . (73) Proprietor: Boehringer Ingelheim Chemicals, Inc. NEW YORK XP002235853 page 2664 -page 2669 Peterburg, VA 23805 (US) • DATABASE CROSSFIRE BEILSTEIN [Online] BEILSTEIN INSTITUT ZUR FOEDERUNG DER (72) Inventors: CHEMISCHEN WISSENSCHAFTEN, • BOSWELL, Robert F., FRANKFURT AM MAIN, DE; Boehringer Ingelheim Chem. -
Metabolomics Analysis Reveals Large Effects of Gut Microflora on Mammalian Blood Metabolites
Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites William R. Wikoffa, Andrew T. Anforab, Jun Liub, Peter G. Schultzb,1, Scott A. Lesleyb, Eric C. Petersb, and Gary Siuzdaka,1 aDepartment of Molecular Biology and Center for Mass Spectrometry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037; and bGenomics Institute of the Novartis Research Foundation, San Diego, CA 92121 Communicated by Steve A. Kay, University of California at San Diego, La Jolla, CA, December 19, 2008 (received for review December 12, 2008) Although it has long been recognized that the enteric community of found to extract energy from their food more efficiently compared bacteria that inhabit the human distal intestinal track broadly impacts with lean counterparts due to alterations in the composition of their human health, the biochemical details that underlie these effects gut microflora that resulted in an increased complement of genes remain largely undefined. Here, we report a broad MS-based metabo- for polysaccharide metabolism (10). It has also been observed that lomics study that demonstrates a surprisingly large effect of the gut bile salt hydrolase encoding genes are enriched in the gut micro- ‘‘microbiome’’ on mammalian blood metabolites. Plasma extracts biome, and that enteric bacteria carry out a wide range of bile acid from germ-free mice were compared with samples from conventional modifications (6, 14). These metagenomic studies suggest that the (conv) animals by using various MS-based methods. Hundreds of metabolites derived from this diverse microbial community can features were detected in only 1 sample set, with the majority of have a direct role in human health and disease. -
Federal Register/Vol. 85, No. 76/Monday, April 20, 2020/Notices
Federal Register / Vol. 85, No. 76 / Monday, April 20, 2020 / Notices 21889 Controlled substance Drug code Schedule Desomorphine ................................................................................................................................................................. 9055 I Dihydromorphine ............................................................................................................................................................. 9145 I Heroin .............................................................................................................................................................................. 9200 I Morphine-N-oxide ............................................................................................................................................................ 9307 I Normorphine .................................................................................................................................................................... 9313 I Tilidine ............................................................................................................................................................................. 9750 I Alpha-methylfentanyl ....................................................................................................................................................... 9814 I Acetyl Fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide) ............................................................................... 9821 I Methamphetamine -
Metabolism of [IC ]Methamphetamine in Man, the Guinea Pig and the Rat
Biochem. J. (1972) 129, 11-22 11 Printed in Great Britain Metabolism of [IC ]Methamphetamine in Man, the Guinea Pig and the Rat By J. CALDWELL, L. G. DRING and R. T. WILLIAMS Department of Biochemistry, St. Mary's Hospital Medical School, London W.2, U.K. (Received 2 March 1972) 1. The metabolites of (±)-2-methylamino-1-phenyl[1-14C]propane ([14C]methamphet- amine) in urine were examined in man, rat and guinea pig. 2. In two male human subjects receiving the drug orally (20mg per person) about 90% ofthe 14C was excreted in the urine in 4 days. The urine ofthe first day was examined for metabolites, and the main metabolites were the unchanged drug (22% of the dose) and 4-hydroxymethamphetamine (15 %). Minor metabolites were hippuric acid, norephedrine, 4-hydroxyamphetamine, 4-hydroxy- norephedrine and an acid-labile precursor of benzyl methyl ketone. 3. In the rat some 82 % of the dose of '4C (45mg/kg) was excreted in the urine and 2-3 % in the faeces in 3-4 days. In 2 days the main metabolites in the urine were 4-hydroxymethamphetamine (31 % ofdose), 4-hydroxynorephedrine (16 %) and unchanged drug (11 %). Minor metabo- lites were amphetamine, 4-hydroxyamphetamine and benzoic acid. 4. The guinea pig was injected intraperitoneally with the drug at two doses, 10 and 45mg/kg. In both cases nearly 90% of the 14C was excreted, mainly in the urine after the lower dose, but in the urine (69%) and faeces (18%) after the higher dose. The main metabolites in the guinea pig were benzoic acid and its conjugates. -
Recommended Methods for the Identification and Analysis Of
Vienna International Centre, P.O. Box 500, 1400 Vienna, Austria Tel: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org RECOMMENDED METHODS FOR THE IDENTIFICATION AND ANALYSIS OF AMPHETAMINE, METHAMPHETAMINE AND THEIR RING-SUBSTITUTED ANALOGUES IN SEIZED MATERIALS (revised and updated) MANUAL FOR USE BY NATIONAL DRUG TESTING LABORATORIES Laboratory and Scientific Section United Nations Office on Drugs and Crime Vienna RECOMMENDED METHODS FOR THE IDENTIFICATION AND ANALYSIS OF AMPHETAMINE, METHAMPHETAMINE AND THEIR RING-SUBSTITUTED ANALOGUES IN SEIZED MATERIALS (revised and updated) MANUAL FOR USE BY NATIONAL DRUG TESTING LABORATORIES UNITED NATIONS New York, 2006 Note Mention of company names and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. ST/NAR/34 UNITED NATIONS PUBLICATION Sales No. E.06.XI.1 ISBN 92-1-148208-9 Acknowledgements UNODC’s Laboratory and Scientific Section wishes to express its thanks to the experts who participated in the Consultative Meeting on “The Review of Methods for the Identification and Analysis of Amphetamine-type Stimulants (ATS) and Their Ring-substituted Analogues in Seized Material” for their contribution to the contents of this manual. Ms. Rosa Alis Rodríguez, Laboratorio de Drogas y Sanidad de Baleares, Palma de Mallorca, Spain Dr. Hans Bergkvist, SKL—National Laboratory of Forensic Science, Linköping, Sweden Ms. Warank Boonchuay, Division of Narcotics Analysis, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand Dr. Rainer Dahlenburg, Bundeskriminalamt/KT34, Wiesbaden, Germany Mr. Adrian V. Kemmenoe, The Forensic Science Service, Birmingham Laboratory, Birmingham, United Kingdom Dr. Tohru Kishi, National Research Institute of Police Science, Chiba, Japan Dr. -
HIPPURIC ACID in Urine 8300
HIPPURIC ACID in urine 8300 C6H5CONHCH2COOH MW: 179.18 CAS: 495-69-2 RTECS: MR8150000 METHOD: 8300, Issue 2 EVALUATION: PARTIAL Issue 1: 15 February 1984 Issue 2: 15 August 1994 BIOLOGICAL INDICATOR OF: exposure to toluene. SYNONYMS: N-benzoylglycine SAMPLING MEASUREMENT SPECIMEN: urine, end of shift after 2 days exposure TECHNIQUE: VISIBLE ABSORPTION SPECTROPHOTOMETRY VOLUME: 50 to 100 mL in 125-mL plastic bottle ANALYTE: complex of hippuric acid PRESERVATIVE: a few crystals of thymol; keep at about and benzenesulfonyl chloride 4 °C WAVELENGTH: 410 nm SHIPMENT: pack in insulated shipper with bagged refrigerant; ship by air express PATH LENGTH: 1 cm SAMPLE CALIBRATION: aqueous hippuric acid standards STABILITY: stable 1 day @ 20 °C; 1 week @ 4 C; and 2 months @ •20 C QUALITY CONTROLS: frozen pooled urine; correct for creatinine content CONTROLS: collect pre-shift urines as well as urines from non-exposed controls RANGE: 0.005 to 0.5 g/L (1:5 urine dilution) ESTIMATED LOD: 0.002 g/L PRECISION (S r): 0.06 ACCURACY: not determined APPLICABILITY: Toluene is metabolized by the body and is excreted in the urine as hippuric acid, the glycine congugate of benzoic acid. This method is useful in screening workers exposed to toluene in the absence of xylene or styrene. The lat ter 2 compounds produce metabolites that are measured as "hippuric acid." INTERFERENCES: In addition to positive interferences from styrene and xylene in the workplace, the ingestion of sodium benzoate in food, salicylic acid, or aspirin by the worker will produce a positive interference. A careful work history/ questionnaire is suggested. -
Product Monograph
PRODUCT MONOGRAPH VYVANSE®* lisdexamfetamine dimesylate Capsules: 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg Chewable Tablets: 10 mg, 20 mg, 30 mg, 40 mg, 50 mg and 60 mg Central Nervous System Stimulant Takeda Canada Inc. Date of Preparation: 22 Adelaide Street West, Suite 3800 19 February 2009 Toronto, Ontario M5H 4E3 Date of Revision: July 21, 2020 Submission Control No.: 240669 *VYVANSE® and the VYVANSE Logo are registered trademarks of Shire LLC, a Takeda company. Takeda and the Takeda Logo are trademarks of Takeda Pharmaceutical Company Limited, used under license. © 2020 Takeda Pharmaceutical Company Limited. All rights reserved. Pa ge 1 of 60 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .................................................... 3 SUMMARY PRODUCT INFORMATION ................................................................... 3 INDICATIONS AND CLINICAL USE ........................................................................ 3 CONTRAINDICATIONS ............................................................................................ 5 WARNINGS AND PRECAUTIONS ............................................................................ 6 ADVERSE REACTIONS........................................................................................... 12 DRUG INTERACTIONS ........................................................................................... 23 DOSAGE AND ADMINISTRATION ........................................................................ 25 OVERDOSAGE ....................................................................................................... -
Or Methionine, for Detoxication Mechanisms
GROWTH-INHIBITION PRODUCED IN RATS BY THE ORAL ADMINISTRATION OF SODIUM BENZOATE EFFECTS OF VARIOUS DIETARY SUPPLEMENTS* ABRAHAM WHITE Growth inhibition in rats has been produced by the incorpora- tion of a variety of toxic compounds into the diet.2" 22, 23, Further, it has been possible to demonstrate that stimulation of growth occurs under these experimental conditions when one of the sulfur-contain- ing amino acids, cysteine, cystine, or methionine, is superimposed on the basal diet still containing the growth-inhibitory compound. Under these conditions the animals resume growth at a rate com- parable to that observed on the basal diet alone. In addition, other substances, e.g., glutathione and cystine disulfoxide, which are known to stimulate growth in rats stunted by one of the so-called "cystine- deficient" diets, have also been shown to be effective growth stimu- lators when added to the basal, growth-inhibiting diets. Inasmuch as these growth-promoting dietary supplements exert their action when injected subcutaneously, as well as following oral administra- tion, it has been concluded that their effect is a true metabolic one and not due to a reaction occurring in the intestine prior to absorption. The specific and unique capacity of the sulfur-containing amino acids, and of substances behaving in nutrition experiments in a man- ner similar to these amino acids, to stimulate the growth of animals ingesting a growth-inhibitory basal diet has led to the suggestion that the inhibition of the growth of the rat by certain organic compounds "is a manifestation of the production of a specific deficiency in the sulfur-containing amino acids, probably by imposing on the organism an increased requirement for organic sulfur, in the form of cystine or methionine, for detoxication mechanisms."' However, although direct proof for the formation of a detoxication product (mercap- turic acid) is clearly established for the monohalogen benzenes, and * From the Department of Physiological Chemistry, Yale University School of Medicine. -
Studies of Synthetic Particles and Nerve Endings on Mass
STUDIES OF SYNTHETIC PARTICLES AND NERVE ENDINGS ON MASS TRANSPORT AND KINETICS AND INHIBITION OF THE DEGLYCOSYLATED DOPAMINE TRANSPORTER By VERONICA MANLING CHIU A dissertation submitted in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY WASHINGTON STATE UNIVERSITY Department of Chemistry May 2012 To the Faculty of Washington State University: The members of the Committee appointed to examine the dissertation of VERONICA MANLING CHIU find it satisfactory and recommend that it be accepted. __________________________________ James O. Schenk, Ph.D., Chair ___________________________________ Herbert H. Hill, Jr., Ph.D. ___________________________________ Chulhee Kang, Ph.D. ___________________________________ Barbara A. Sorg, Ph.D. ii ACKNKOWLEDGEMENTS I would like to start by thanking my committee, Drs. Jim Schenk, Herb Hill, Chulhee Kang, and Barb Sorg for their support, encouragement, and guidance. I am especially grateful to my mentor as well as my friend, Dr. Jim Schenk, for the infinite support, patience, and encouragement. Jim, you allowed me to learn, think and find answers on my own, but at the same time you provided help whenever I needed it. You also encouraged me to believe who I am. You taught me how to write a scientific paper and allowed me to write in my own words. You also provided me much help with giving presentations, which I am still learning about. In addition to science knowledge, I learned a lot from you on cooking, food, American culture, and arts. I really enjoyed the time when we gathered and shared food, and of course, your food is always so tasty. I know I am going to miss it! I also enjoyed our talks, and I never met a person who has as much knowledge as you do. -
Review: Synthetic Methods for Amphetamine
Review: Synthetic Methods for Amphetamine A. Allen1 and R. Ely2 1Array BioPharma Inc., Boulder, Colorado 80503 2Drug Enforcement Administration, San Francisco, CA Abstract: This review focuses on synthesis of amphetamine. The chemistry of these methods will be discussed, referenced and precursors highlighted. This review covers the period 1985 to 2009 with emphasis on stereoselective synthesis, classical non-chiral synthesis and bio-enzymatic reactions. The review is directed to the Forensic Community and thus highlights precursors, reagents, stereochemistry, type and name reactions. The article attempts to present, as best as possible, a list of references covering amphetamine synthesis from 1900 -2009. Although this is the same fundamental ground as the recent publication by K. Norman; “Clandestine Laboratory Investigating Chemist Association” 19, 3(2009)2-39, this current review offers another perspective. Keywords: Review, Stereoselective, Amphetamine, Syntheses, references, Introduction: It has been 20 years since our last review of the synthetic literature for the manufacture of amphetamine and methamphetamine. Much has changed in the world of organic transformation in this time period. Chiral (stereoselective) synthetic reactions have moved to the forefront of organic transformations and these stereoselective reactions, as well as regio-reactions and biotransformations will be the focus of this review. Within the synthesis of amphetamine, these stereoselective transformations have taken the form of organometallic reactions, enzymatic reactions, ring openings, - aminooxylations, alkylations and amination reactions. The earlier review (J. Forensic Sci. Int. 42(1989)183-189) addressed for the most part, the ―reductive‖ synthetic methods leading to this drug of abuse. It could be said that the earlier review dealt with ―classical organic transformations,‖ roughly covering the period from 1900-1985. -
State Methamphetamine Precursor Control Policies
The author(s) shown below used Federal funds provided by the U.S. Department of Justice and prepared the following final report: Document Title: From Policy to Practice: State Methamphetamine Precursor Control Policies Author: Jean O’Connor, J.D., M.P.H.; Jamie Chriqui, Ph.D., M.H.S.; Duane McBride, Ph.D.; Shelby Smith Eidson, J.D.; Carissa Baker; Yvonne Terry-McElrath, M.S.; Curt VanderWaal, Ph.D. Document No.: 228133 Date Received: August 2009 Award Number: 2005-IJ-CX-0028 This report has not been published by the U.S. Department of Justice. To provide better customer service, NCJRS has made this Federally- funded grant final report available electronically in addition to traditional paper copies. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S. Department of Justice. From Policy to Practice: State Methamphetamine Precursor Control Policies A report on state methamphetamine laws and regulations, effective October 1, 2005 Prepared by: Jean O’Connor, J.D., M.P.H.1 Jamie Chriqui, Ph.D., M.H.S.1 Duane McBride, Ph.D.2 Shelby Smith Eidson, J.D.1 Carissa Baker1 Yvonne Terry-McElrath, M.S.3 Curt VanderWaal, Ph.D. 2 1The MayaTech Corporation 2Andrews University 3University of Michigan March 2, 2007 This document is a research report submitted to the U.S. Department of Justice. This report has not been published by the Department. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S.